GenePeeks Announces Partnership with Fertility SOURCE Companies
Continued Momentum for Preconception Screen
CAMBRIDGE, Mass.–(BUSINESS WIRE)–GenePeeks,
Inc., a computational genomics company focused on transforming
genetic disease risk analysis, today announced a new partnership with Fertility
SOURCE Companies® and its two divisions: The Donor SOURCE™, a
premier egg donation agency, and The Surrogacy SOURCE™, a specialized
gestational surrogacy program. This announcement signals continued
momentum for GenePeeks Preconception Screen, which identifies the
combined parental risk of passing on more than 1,000 serious genetic
diseases.
Fertility SOURCE clients may now select the GenePeeks test to assess a
future child’s risk of disease inheritance, a service that includes
consultation with a certified genetic counselor. Donor SOURCE™ donors
now have the option to complete pre-test protocols and be identified as
“GenePeeks Ready,” which may save prospective parents significant time
in their fertility journey.
“We are delighted to partner with Fertility SOURCE Companies,” said Anne
Morriss, Chief Executive Officer and Co-Founder of GenePeeks. “As one of
the largest egg donor and surrogacy agencies in the country, this
collaboration will enable us to expand our physician network and give an
increasing number of patient families access to our advanced analytics
platform.”
Steve Masler, Chief Executive Officer of Fertility SOURCE Companies
said, “Fertility SOURCE Companies are committed to the highest degree of
compassion and skilled care. GenePeeks’ technology covers an expanded
number of inherited diseases with a depth that far exceeds other genetic
tests on the market. We’re thrilled to partner with GenePeeks to help
our clients make more informed decisions about the future health of
their children.”
About GenePeeks’ Technology
GenePeeks’ comprehensive
approach, called Virtual Progeny Analytics (VPA), uniquely integrates
simulated DNA information from two genetic participants to predict the
future genome of a child prior to conception. For every mutation in
these hypothetical genomes, the company computes a proprietary Variant
Gene Dysfunction (VGD) score that predicts gene function and associated
disease risk. This next generation approach allows GenePeeks to cover an
expanded number of diseases with increased sensitivity and evaluate
variants that may remain uncharacterized by other genetic tests, while
avoiding the confusion and anxiety that can be associated with carrier
testing. In contrast to carrier screening, which identifies parental
carrier status, GenePeeks focuses on a future child’s true risk of
disease inheritance. GenePeeks offers this physician-ordered service
through its CLIA certified clinical laboratory.
About GenePeeks
GenePeeks is a computational genomics
company focused on identifying inherited disease risk in future
generations. GenePeeks’ patented technology digitally combines the
genetic information of two potential parents, simulating the complex
genetic interactions that occur naturally in human reproduction. The
company’s proprietary platform creates and analyzes thousands of Virtual
Progeny to uncover disease risk that cannot be seen with alternative
screening tools. GenePeeks offers this physician-ordered service through
its CLIA certified clinical laboratory.
GenePeeks is privately held, with corporate offices in Cambridge, Mass.
For more information, visit www.genepeeks.com
GenePeeks’ next-generation screening technology is available today. For
more information about becoming a partner, please contact support@genepeeks.com
About Fertility SOURCE Companies®
Fertility SOURCE Companies
(The Donor SOURCE™ & The Surrogacy SOURCE™) was established in 2003 with
a mission to provide individuals who are unable to conceive with the
assistance they need to become parents, including matching them with an
egg donor, gestational surrogates or both. As one of the largest egg
donor and surrogacy agencies operating on a national level in the United
States, Fertility SOURCE Companies is proud to provide comprehensive
third party reproductive care and coordination and has helped thousands
of parents build their families. Through its divisions, The Donor SOURCE
and The Surrogacy SOURCE, the company’s commitment is to provide the
highest degree of compassion, support and guidance to recipients, egg
donors and surrogates. For more information, visit www.fertilitysourcecompanies.com
Contacts
Feinstein Kean Healthcare
Deborah Hernandez, 617-761-6731
Deborah.Hernandez@fkhealth.com
or
Feinstein
Kean Healthcare
Lisa Rivero, 617-761-6746
Lisa.Rivero@fkhealth.com
